Literature DB >> 21358557

Proximal symphalangism, hyperopia, conductive hearing impairment, and the NOG gene: 2 new mutations.

Henricus G X M Thomeer1, Ronald J C Admiraal, Lies Hoefsloot, Henricus P M Kunst, Cor W R J Cremers.   

Abstract

OBJECTIVES: To report on 2 families with proximal symphalangism syndrome and 2 new NOG gene mutations and to report on the outcomes of exploratory tympanotomy. STUDY
DESIGN: Retrospective chart study.
SETTING: Tertiary referral center. PATIENTS: A total of 6 patients, one of which underwent an exploratory tympanotomy, were examined from 2 families. INTERVENTION: Exploratory tympanotomy in 1 patient. MAIN OUTCOME MEASURES: Medical and otologic histories and postoperative hearing outcomes.
RESULTS: In the patient that was operated upon, the preoperative air conduction hearing threshold of 55 dB was reduced to 41 dB with a residual air bone gap of 21 dB. Furthermore, deoxyribonucleic acid analysis revealed 2 different mutations: a heterozygous nonsense mutation in the NOG gene, c.391C>T (p.Gln131X), and a frameshift mutation in the NOG gene (NOG, c.304del (p.Ala102fs)).
CONCLUSION: NOG gene mutations, which lead to aberrant noggin protein function, give rise to a large spectrum of clinical findings and different symphalangism syndromes. These syndromes are all allelic disorders within the Noggin phenotype spectrum. We report on 2 new mutations that are supplementary to those previously described in the literature.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358557     DOI: 10.1097/MAO.0b013e318211fada

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  8 in total

1.  Identification of two novel mutations in the NOG gene associated with congenital stapes ankylosis and symphalangism.

Authors:  Akira Ganaha; Tadashi Kaname; Yukinori Akazawa; Teruyuki Higa; Ayano Shinjou; Kenji Naritomi; Mikio Suzuki
Journal:  J Hum Genet       Date:  2014-11-13       Impact factor: 3.172

2.  Molecular and clinical delineation of the 17q22 microdeletion phenotype.

Authors:  Tobias Laurell; Johanna Lundin; Britt-Marie Anderlid; Jerome L Gorski; Giedre Grigelioniene; Samantha J L Knight; Ana C V Krepischi; Agneta Nordenskjöld; Susan M Price; Carla Rosenberg; Peter D Turnpenny; Angela M Vianna-Morgante; Ann Nordgren
Journal:  Eur J Hum Genet       Date:  2013-01-30       Impact factor: 4.246

3.  Mutations in the NOG gene are commonly found in congenital stapes ankylosis with symphalangism, but not in otosclerosis.

Authors:  S Usami; S Abe; S Nishio; Y Sakurai; H Kojima; T Tono; N Suzuki
Journal:  Clin Genet       Date:  2012-01-30       Impact factor: 4.438

4.  Identification of a novel mutation of NOG in family with proximal symphalangism and early genetic counseling.

Authors:  Cong Ma; Lv Liu; Fang-Na Wang; Hai-Shen Tian; Yan Luo; Rong Yu; Liang-Liang Fan; Ya-Li Li
Journal:  BMC Med Genet       Date:  2019-11-06       Impact factor: 2.103

5.  Genetic and clinical phenotypic analysis of familial stapes sclerosis caused by an NOG mutation.

Authors:  Rong Yu; Hongqun Jiang; Huihuang Liao; Wugen Luo
Journal:  BMC Med Genomics       Date:  2020-12-11       Impact factor: 3.063

6.  Genetic Heterogeneity and Core Clinical Features of NOG-Related-Symphalangism Spectrum Disorder.

Authors:  Ryan J Carlson; Alicia Quesnel; Dawson Wells; Zippora Brownstein; Dror Gilony; Suleyman Gulsuner; Kathleen A Leppig; Karen B Avraham; Mary-Claire King; Tom Walsh; Jay Rubinstein
Journal:  Otol Neurotol       Date:  2021-09-01       Impact factor: 2.619

7.  A novel nonsense mutation in the NOG gene causes familial NOG-related symphalangism spectrum disorder.

Authors:  Kenichi Takano; Noriko Ogasawara; Tatsuo Matsunaga; Hideki Mutai; Akihiro Sakurai; Aki Ishikawa; Tetsuo Himi
Journal:  Hum Genome Var       Date:  2016-08-04

8.  Novel NOG (p.P42S) mutation causes proximal symphalangism in a four-generation Chinese family.

Authors:  Yanwei Sha; Ding Ma; Ning Zhang; Xiaoli Wei; Wensheng Liu; Xiong Wang
Journal:  BMC Med Genet       Date:  2019-08-01       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.